Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFTNASDAQ:HOWLNASDAQ:MDWDNASDAQ:NBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGenfit$3.44-2.4%$3.69$3.11▼$6.42$171.74M1.1313,466 shs1,639 shsHOWLWerewolf Therapeutics$0.88+0.7%$1.27$0.86▼$6.89$39.00M0.37383,522 shs17,950 shsMDWDMediWound$16.22+0.9%$17.88$12.78▼$24.00$175.01M0.8289,585 shs6,000 shsNBTXNanobiotix$3.58$3.59$2.76▼$7.51$168.74M0.2821,408 shs13,780 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGenfit+0.47%+0.76%-0.98%-7.39%-3.48%HOWLWerewolf Therapeutics-10.46%-19.40%-29.80%-41.18%-86.36%MDWDMediWound+3.54%-3.54%-3.19%-9.72%+13.41%NBTXNanobiotix-2.51%-3.46%-5.14%+21.60%-43.71%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGenfit1.9634 of 5 stars3.54.00.00.02.20.00.0HOWLWerewolf Therapeutics2.5116 of 5 stars3.51.00.00.02.63.30.6MDWDMediWound1.4424 of 5 stars3.51.00.00.01.10.80.6NBTXNanobiotix2.6029 of 5 stars3.35.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGenfit 3.00Buy$13.00278.46% UpsideHOWLWerewolf Therapeutics 3.00Buy$9.00926.23% UpsideMDWDMediWound 3.00Buy$31.3393.19% UpsideNBTXNanobiotix 2.67Moderate Buy$12.00235.20% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, GNFT, NBTX, and MDWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/12/2025HOWLWerewolf TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/28/2025MDWDMediWoundCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$39.002/17/2025NBTXNanobiotixUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold2/7/2025GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.001/14/2025HOWLWerewolf TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $4.001/10/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGenfit$76.06M2.26N/AN/A$1.48 per share2.32HOWLWerewolf Therapeutics$1.89M20.86N/AN/A$3.08 per share0.28MDWDMediWound$20.22M8.66N/AN/A$3.43 per share4.73NBTXNanobiotix$36.22M4.66N/AN/A($0.04) per share-89.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A4/3/2025 (Estimated)HOWLWerewolf Therapeutics-$37.37M-$1.66N/AN/AN/A-578.80%-58.83%-38.45%5/2/2025 (Estimated)MDWDMediWound-$6.72M-$3.07N/AN/AN/A-142.29%-82.17%-33.67%5/27/2025 (Estimated)NBTXNanobiotix-$42.97MN/A0.00N/AN/AN/AN/AN/A4/2/2025 (Estimated)Latest HOWL, GNFT, NBTX, and MDWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/23/2025N/ANBTXNanobiotix-$0.5834N/AN/AN/A$3.55 millionN/A4/2/2025N/ANBTXNanobiotix-$0.5834-$0.5834N/AN/A$3.55 million$3.55 million3/19/2025Q4MDWDMediWound-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 million3/11/2025Q4 2024HOWLWerewolf Therapeutics-$0.43-$0.46-$0.03-$0.46$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGenfitN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGenfit0.613.743.74HOWLWerewolf Therapeutics0.2910.1010.10MDWDMediWoundN/A2.111.99NBTXNanobiotixN/A1.42N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGenfit2.24%HOWLWerewolf Therapeutics64.84%MDWDMediWound46.83%NBTXNanobiotix38.81%Insider OwnershipCompanyInsider OwnershipGNFTGenfit4.20%HOWLWerewolf Therapeutics21.10%MDWDMediWound9.20%NBTXNanobiotix3.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableHOWLWerewolf Therapeutics4044.83 million35.16 millionOptionableMDWDMediWound8010.79 million9.79 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableHOWL, GNFT, NBTX, and MDWD HeadlinesRecent News About These CompaniesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)April 2 at 7:57 AM | theglobeandmail.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025March 31 at 2:00 AM | globenewswire.comNanobiotix reports promising NSCLC treatment study resultsMarch 29, 2025 | investing.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Down 68.6% in MarchMarch 28, 2025 | marketbeat.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNanobiotix (NBTX) to Release Quarterly Earnings on MondayMarch 23, 2025 | marketbeat.comLeerink Partnrs Predicts Higher Earnings for NanobiotixMarch 22, 2025 | marketbeat.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)March 21, 2025 | djournal.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceMarch 20, 2025 | globenewswire.comNanobiotix amends global licensing agreement with Janssen PharmaceuticaMarch 18, 2025 | markets.businessinsider.comNanobiotix S.A. (NASDAQ:NBTX) Short Interest Up 37.6% in FebruaryMarch 17, 2025 | marketbeat.comNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026March 17, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Shares Up 6.7% - Here's WhyMarch 13, 2025 | marketbeat.comNanobiotix files $200M mixed securities shelfMarch 7, 2025 | markets.businessinsider.comNanobiotix files to sell 5.62M ordinary shares for holdersMarch 7, 2025 | markets.businessinsider.comNanobiotix downgraded to Neutral from Buy at UBSFebruary 17, 2025 | markets.businessinsider.comUBS downgrades Nanobiotix (NBTX) to a HoldFebruary 17, 2025 | markets.businessinsider.com7 Best Nanotech Penny Stocks to Invest InFebruary 14, 2025 | insidermonkey.comIs Nanobiotix (NBTX) the Best Nanotech Penny Stock to Invest In?February 14, 2025 | insidermonkey.comNanobiotix to Participate in Multiple Investor Conferences in February and March 2025January 29, 2025 | globenewswire.comNanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC StudyJanuary 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, GNFT, NBTX, and MDWD Company DescriptionsGenfit NASDAQ:GNFT$3.44 -0.09 (-2.41%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Werewolf Therapeutics NASDAQ:HOWL$0.88 +0.01 (+0.75%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.MediWound NASDAQ:MDWD$16.22 +0.15 (+0.93%) As of 10:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Nanobiotix NASDAQ:NBTX$3.58 0.00 (0.00%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
